LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Abierto

SectorSanidad

10.11 -2.22

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.08

Máximo

10.85

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.094 49.888
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+54.84% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1.9B
Apertura anterior	12.33
Cierre anterior	10.11

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

8 / 344 Clasificación en Healthcare

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jun 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 jun 2026, 23:45 UTC

Adquisiciones, fusiones, absorciones

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 jun 2026, 23:44 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 jun 2026, 23:43 UTC

Adquisiciones, fusiones, absorciones

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 jun 2026, 23:35 UTC

Charlas de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 jun 2026, 22:06 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 jun 2026, 22:05 UTC

Adquisiciones, fusiones, absorciones

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 jun 2026, 20:51 UTC

Ganancias

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 20:09 UTC

Charlas de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 jun 2026, 19:36 UTC

Charlas de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 jun 2026, 19:32 UTC

Charlas de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 jun 2026, 19:25 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 jun 2026, 19:00 UTC

Charlas de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 jun 2026, 18:52 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 jun 2026, 18:47 UTC

Charlas de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 jun 2026, 18:37 UTC

Charlas de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 jun 2026, 18:27 UTC

Charlas de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 jun 2026, 17:35 UTC

Charlas de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 jun 2026, 17:30 UTC

Charlas de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 jun 2026, 16:34 UTC

Charlas de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jun 2026, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jun 2026, 15:28 UTC

Charlas de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 jun 2026, 15:25 UTC

Charlas de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

54.84% repunte

Estimación a 12 Meses

Media 16.8 USD 54.84%

Máximo 20 USD

Mínimo 13.6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Sentimiento

By Acuity

8 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.